inside tracker
inside tracker

Senescence

Longevity companies to watch in 2021

As the world enters the new year with a vaccine and an increased focus on geroprotection, there’s much to look forward to. Research from the...

A year in Longevity: progress perspectives

2020's journey to extending healthy human Longevity. The journey to Longevity has many stages, whether it's a clinical pipeline, gaining regulatory approval for a drug,...

A year in Longevity: founders’ perspectives

Speaking to the innovators behind some of Longevity’s most exciting companies. Continuing our look back at some of the highlights of 2020, we thought we’d...

Eliminating senescent cells to improve heart attack recovery

A drug that exterminates senescent cells improves recovery after a heart attack, according to new research, and could pave the way for a new...

Healthy aging signs in telomeres found in new supplement study

Study of effect of ergothioneine on telomeres found signs of healthy aging. An in vitro study published in the Journal of Dietary Supplements, has demonstrated...

NAD boosting to reverse senescence and inflammaging

Senescent cells promote NAD tissue decline during aging through CD38 enzymes which can now become a novel therapeutic target. Nicotinamide adenine dinucleotide (NAD) is a...

Simulations open the door to cell aging reversal

Switching off a newly-identified enzyme could reverse senescence, spotlighting a potential therapy avenue. Researchers at the Korea Advanced Institute of Science and Technology (KAIST) have...

Silicon Valley is waking up to Longevity and senolytics

Silicon Valley's Rubedo Life Sciences closes $12m seed round for proprietary drug discovery platform that targets senolytics. Following-on from BioAge's funding announcement another biotech start-up...

Hyperbaric oxygen therapy: a commercial Longevity treatment?

Hyperbaric oxygen therapy can significantly decrease aging characteristics – does it have a future as a commercial Longevity treatment? Aging is made up of many...

Senescence: a new weapon in the fight against cancer

Targeting senescent “zombie” cells may improve cancer survival rates. How well women with cervical cancer respond to treatment (and survive) correlates with the level of...

Found: the missing link in the Longevity ‘supply-chain’

Co-founder of new Longevity course for physicians reveals plans to expand the program to science students and, ultimately, everyone. Following yesterday’s news about the launch...

Let’s initiate trials of potential geroprotective therapies

Dr Lynne Cox explains the importance of geroprotectors – especially during COVID-19. This month The Lancet launches its own journal on Longevity, publishing clinically-focused Longevity and...

Using senolytics to treat fibrosis shows promise

Increasing evidence shows a direct link between fibrosis in the extracellular matrix and cellular senescence. Mounting evidence suggests a direct link between cellular senescence...

AgelessRx and funding an IRB-approved rapamycin trial

Rapamycin could be the PEARL in the Longevity oyster as new human trial seeks funding. AgelessRx is a platform that sells drugs and supplements including...

Inflammaging – could ibuprofen be the answer?

Neurodegenerative disease is associated with age-related chronic, low grade inflammation, but studies suggest that this could be reversed with over the counter NSAIDs. In an...

NAD-boosting may stabilise telomeres to slow aging

A recent study shows that nicotinamide riboside helps alleviate telomere dysfunction in human cells. The length of telomeres decreases with age, and telomere dysfunction...

OneSkin launches topical senetherapeutic skin treatment

Extending skinspan with non-invasive senetherapeutic proprietary peptide. OneSkin is a Longevity company on a mission to transform the way we think about skin. Today the...

Why government must unlock biotech’s potential to maximise Longevity

Breanna Deutsch joins us for a guest editorial to advocate for the increased prioritisation of government funding for Longevity in the US. Breanna Deutsch has...

Time to haul SASP (back to the beginning)

New study demonstrates links between protein and the toxin-producing senescence phenotype. Senescent cells have stopped dividing and stopped being useful, but haven't read the "time...

Big pharma enters senolytic drug discovery programme

Japanese pharma Taisho teams with Insilico to discover novel molecules that will tackle aging. It was announced today that Taisho Pharmaceutical and Insilico Medicine have...
inside tracker
lumen

Latest articles